Wellmune Beta Glucan Scientific Research

On this page we present some of the many studies on Wellmune® Beta Glucan and immune system health. Wellmune is supported by more than $350M worth of research and development with numerous human clinical trials, many of which have been published several times in peer-reviewed journals. Wellmune beta glucans are protected by 40 patents and patents pending in several countries. This is no doubt one of the best documented yeast beta glucans around, and so far our favourite functional ingredient for optimal immune health.

Wellmune was developed by Biothera and is now owned by Kerry Group. The patented functional ingredient is extracted from a proprietary yeast strain with unique characteristics. Wellmune research published in Nature has demonstrated that molecular structure, particle size and manufacturing process is crucial for biological activity and the receptor binding required to prime innate immune system cells for activity.

A bit misleadingly, supplements with mushroom, oat and other brands of yeast beta glucans still reference research originating from Biothera’s development of Wellmune Beta Glucan, which of course may not be accurate (in particular for mushroom and oat derived beta glucans) in terms of potential immune system health benefits.

Wellmune Beta Glucan Research Overview

Wellmune Beta Glucan – Clinical Research

• Immune-Boosting Wellmune Beta Glucan in ImmiFlex Supports Health of Older Adults – Jun, 2014
• Proof of Efficacy on key ingredient in ImmiFlex Wellmune WGP Beta Glucan – Clinical human studies overview 2014, 9 studies. – February, 2014
• Biothera beta 1,3/1,6 glucan clinical research, preclinical research and baker’s yeast beta glucan analysis is the subject of peer-reviewed science and medical journal articles and presentations at scientific forums, overview. – February, 2014
• Differential regulation of oxidative burst by distinct Beta-glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells – Feb, 2014
• Wellmune WGP Reduced in this Study Upper Respiratory Tract Infection Symptoms by 40% among Marathoners – 2013
• Wellmune WGP Reduces Immune Suppression Associated with Strenuous Exercise – 2012
• Wellmune WGP Reduced Upper Respiratory Tract Infection Symptoms during 90-Day Lifestyle Stress Study – 2012
• Wellmune WGP Reduced Duration of Cold/Flu Symptoms in Study of 100 Medical Students – 2012
• Beta Glucan supplementation, allergy symptoms, and quality of life in self-described ragweed allergy sufferers – 2012
• Biothera’s involvement in a multi-year clinical program to evaluate the efficacy of Wellmune WGP® in humans under various physical and psychological stress situations – Jun, 2010
• Beta 1,3/1,6 glucan decreases upper respiratory tract infection symptoms and improves psychological wellbeing in moderate to highly-stressed subjects – January, 2010
• Wellmune WGP Reduced Health Challenges in High Lifestyle Stress Subjects – 2010
• Beta-glucan supplement reduces upper respiratory tract infections and improves mood state in healthy stressed subjects – 2010
• Therapeutic potential of various ß -glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy – February, 2009
• Maintained Physical Health and Reduced ‘Down Time’ During 90-Day Study – 2009
• Randomised Phase II clinical trials of Wellmune WGP® for immune support during cold and flu season – 2009
• Wellmune WGP Reduced Fatigue and Improved Health in Marathon Runners – 2009
• Effect of BETA 1, 3/1, 6 GLUCAN on upper respiratory tract infection symptoms and mood state in marathon athletes – 2009
• Wildland Firefighters Reported Improved Health with Wellmune WGP – 2008
• Effects of an Immunomodulating supplement on upper respiratory tract infection symptoms in wildland firefighters – May, 2008
• Wellmune WGP Cold & Flu Study – 2007-2010

Wellmune Beta Glucan – Preclinical Research

• Differential Pathways Regulating Innate and Adaptive Anti-tumor Immune Responses by Particulate and Soluble Yeast-derived Beta-Glucans – Feb, 2009
• Therapeutic Potential of Various Beta-glucan Sources in Conjunction with Anti-tumor Monoclonal Antibody in Cancer Therapy – Feb, 2009
• Yeast Beta-Glucan Amplifies Phagocyte Killing of iC3b-Opsonized Tumor Cells via Complement Receptor 3-Syk-Phosphatidylinositol 3-Kinase Pathway1 – Aug, 2006
• C5a-Mediated Leukotriene B4-Amplified Neutrophil Chemotaxis Is Essential in Tumor Immunotherapy Facilitated by Anti-Tumor Monoclonal Antibody and Beta-Glucan1 – Jun, 2005
• Yeast Whole Glucan Particle Beta-glucan in Conjunction with Antitumour Monoclonal Antibodies to Treat Cancer – May, 2005
• Mechanism by Which Orally Administered Beta-1,3-Glucans Enhance the Tumoricidal Activity of AntiTumor Monoclonal Antibodies in Murine Tumor Models – Jul, 2004

Wellmune Beta Glucan – Analytical Research

• Modification of a Beta Glucan Affects Aggregation Behavior and Biological Activity – Aug, 2012
• Activation of the Innate Immune Receptor Dectin-1 upon Formation of a ‘Phagocytic Synapse’ – Apr, 2011
• Enzymatic Method To Measure β-1,3-β-1,6-Glucan Content in Extracts and Formulated Products (GEM Assay) – Sep, 2010
• Analysis of Side Chain Lengths of Branched Beta-1,3-Glucans by Alkaline Degradation – Aug, 2008
• Toxicological assessment of a particulate yeast (1,3/1,6)-Beta-d-glucan in rats – Sep, 2007

 

For more information and studies on beta glucans visit www.wellmune.com

Until we officially launch you can stay updated on Facebook